Centessa Pharmaceuticals plc

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, VRTX has a market cap of 121.3B. Regarding current trading prices, CNTA is priced at $16.36, while VRTX trades at $391.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas VRTX's P/E ratio is -122.99. In terms of profitability, CNTA's ROE is -0.57%, compared to VRTX's ROE of -0.06%. Regarding short-term risk, CNTA is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check VRTX's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, REGN has a market cap of 60.7B. Regarding current trading prices, CNTA is priced at $16.36, while REGN trades at $577.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas REGN's P/E ratio is 14.40. In terms of profitability, CNTA's ROE is -0.57%, compared to REGN's ROE of +0.14%. Regarding short-term risk, CNTA is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check REGN's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, ALNY has a market cap of 55B. Regarding current trading prices, CNTA is priced at $16.36, while ALNY trades at $425.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas ALNY's P/E ratio is -171.25. In terms of profitability, CNTA's ROE is -0.57%, compared to ALNY's ROE of -2.74%. Regarding short-term risk, CNTA is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check ALNY's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, CNTA is priced at $16.36, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas SGEN's P/E ratio is -57.19. In terms of profitability, CNTA's ROE is -0.57%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, CNTA is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check SGEN's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, ARGX has a market cap of 42.2B. Regarding current trading prices, CNTA is priced at $16.36, while ARGX trades at $690.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas ARGX's P/E ratio is 35.18. In terms of profitability, CNTA's ROE is -0.57%, compared to ARGX's ROE of +0.23%. Regarding short-term risk, CNTA is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check ARGX's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, BNTX has a market cap of 26.5B. Regarding current trading prices, CNTA is priced at $16.36, while BNTX trades at $110.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas BNTX's P/E ratio is -30.19. In terms of profitability, CNTA's ROE is -0.57%, compared to BNTX's ROE of -0.04%. Regarding short-term risk, CNTA is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check BNTX's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, SMMT has a market cap of 21.8B. Regarding current trading prices, CNTA is priced at $16.36, while SMMT trades at $30.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas SMMT's P/E ratio is -86.24. In terms of profitability, CNTA's ROE is -0.57%, compared to SMMT's ROE of -0.70%. Regarding short-term risk, CNTA is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check SMMT's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, RPRX has a market cap of 21.3B. Regarding current trading prices, CNTA is priced at $16.36, while RPRX trades at $37.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas RPRX's P/E ratio is 15.46. In terms of profitability, CNTA's ROE is -0.57%, compared to RPRX's ROE of +0.16%. Regarding short-term risk, CNTA is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check RPRX's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, CNTA is priced at $16.36, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas BGNE's P/E ratio is -22.55. In terms of profitability, CNTA's ROE is -0.57%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, CNTA is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check BGNE's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, CNTA is priced at $16.36, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, CNTA's ROE is -0.57%, compared to DNA-WT's ROE of -0.63%. Regarding short-term risk, CNTA is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check DNA-WT's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, INCY has a market cap of 15.2B. Regarding current trading prices, CNTA is priced at $16.36, while INCY trades at $78.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas INCY's P/E ratio is 18.45. In terms of profitability, CNTA's ROE is -0.57%, compared to INCY's ROE of +0.34%. Regarding short-term risk, CNTA is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check INCY's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, GMAB has a market cap of 13.5B. Regarding current trading prices, CNTA is priced at $16.36, while GMAB trades at $22.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas GMAB's P/E ratio is 12.93. In terms of profitability, CNTA's ROE is -0.57%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, CNTA is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check GMAB's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, UTHR has a market cap of 13.2B. Regarding current trading prices, CNTA is priced at $16.36, while UTHR trades at $300.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas UTHR's P/E ratio is 11.41. In terms of profitability, CNTA's ROE is -0.57%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, CNTA is less volatile compared to UTHR. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check UTHR's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, CNTA is priced at $16.36, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas KRTX's P/E ratio is -28.09. In terms of profitability, CNTA's ROE is -0.57%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, CNTA is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check KRTX's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, BMRN has a market cap of 11.6B. Regarding current trading prices, CNTA is priced at $16.36, while BMRN trades at $62.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas BMRN's P/E ratio is 22.34. In terms of profitability, CNTA's ROE is -0.57%, compared to BMRN's ROE of +0.09%. Regarding short-term risk, CNTA is less volatile compared to BMRN. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check BMRN's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, ASND has a market cap of 11.1B. Regarding current trading prices, CNTA is priced at $16.36, while ASND trades at $184.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas ASND's P/E ratio is -27.69. In terms of profitability, CNTA's ROE is -0.57%, compared to ASND's ROE of +1.91%. Regarding short-term risk, CNTA is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check ASND's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, MRNA has a market cap of 10.7B. Regarding current trading prices, CNTA is priced at $16.36, while MRNA trades at $27.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas MRNA's P/E ratio is -3.68. In terms of profitability, CNTA's ROE is -0.57%, compared to MRNA's ROE of -0.27%. Regarding short-term risk, CNTA is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check MRNA's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, EXEL has a market cap of 9.9B. Regarding current trading prices, CNTA is priced at $16.36, while EXEL trades at $37.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas EXEL's P/E ratio is 17.70. In terms of profitability, CNTA's ROE is -0.57%, compared to EXEL's ROE of +0.28%. Regarding short-term risk, CNTA is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check EXEL's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, CNTA is priced at $16.36, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas RXDX's P/E ratio is -56.47. In terms of profitability, CNTA's ROE is -0.57%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, CNTA is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check RXDX's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, BBIO has a market cap of 9.1B. Regarding current trading prices, CNTA is priced at $16.36, while BBIO trades at $47.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas BBIO's P/E ratio is -13.41. In terms of profitability, CNTA's ROE is -0.57%, compared to BBIO's ROE of +0.49%. Regarding short-term risk, CNTA is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check BBIO's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, VRNA has a market cap of 9B. Regarding current trading prices, CNTA is priced at $16.36, while VRNA trades at $105.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas VRNA's P/E ratio is -52.73. In terms of profitability, CNTA's ROE is -0.57%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, CNTA is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check VRNA's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, CNTA is priced at $16.36, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas IMGN's P/E ratio is -111.55. In terms of profitability, CNTA's ROE is -0.57%, compared to IMGN's ROE of -1.43%. Regarding short-term risk, CNTA is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check IMGN's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, TECH has a market cap of 8.6B. Regarding current trading prices, CNTA is priced at $16.36, while TECH trades at $54.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas TECH's P/E ratio is 66.12. In terms of profitability, CNTA's ROE is -0.57%, compared to TECH's ROE of +0.06%. Regarding short-term risk, CNTA is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check TECH's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, CNTA is priced at $16.36, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas BPMC's P/E ratio is -51.58. In terms of profitability, CNTA's ROE is -0.57%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, CNTA is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check BPMC's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, CNTA is priced at $16.36, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas CERE's P/E ratio is -16.47. In terms of profitability, CNTA's ROE is -0.57%, compared to CERE's ROE of -0.43%. Regarding short-term risk, CNTA is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check CERE's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, CNTA is priced at $16.36, while ROIVW trades at $2.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, CNTA's ROE is -0.57%, compared to ROIVW's ROE of -0.03%. Regarding short-term risk, CNTA is less volatile compared to ROIVW. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check ROIVW's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, ROIV has a market cap of 7.8B. Regarding current trading prices, CNTA is priced at $16.36, while ROIV trades at $11.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas ROIV's P/E ratio is -15.35. In terms of profitability, CNTA's ROE is -0.57%, compared to ROIV's ROE of -0.03%. Regarding short-term risk, CNTA is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check ROIV's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, CORT has a market cap of 7.6B. Regarding current trading prices, CNTA is priced at $16.36, while CORT trades at $70.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas CORT's P/E ratio is 64.08. In terms of profitability, CNTA's ROE is -0.57%, compared to CORT's ROE of +0.20%. Regarding short-term risk, CNTA is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check CORT's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, HALO has a market cap of 7.4B. Regarding current trading prices, CNTA is priced at $16.36, while HALO trades at $60.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas HALO's P/E ratio is 15.95. In terms of profitability, CNTA's ROE is -0.57%, compared to HALO's ROE of +1.22%. Regarding short-term risk, CNTA is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check HALO's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, JAZZ has a market cap of 7B. Regarding current trading prices, CNTA is priced at $16.36, while JAZZ trades at $113.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas JAZZ's P/E ratio is 15.77. In terms of profitability, CNTA's ROE is -0.57%, compared to JAZZ's ROE of +0.12%. Regarding short-term risk, CNTA is less volatile compared to JAZZ. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check JAZZ's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, MDGL has a market cap of 6.9B. Regarding current trading prices, CNTA is priced at $16.36, while MDGL trades at $333.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas MDGL's P/E ratio is -17.49. In terms of profitability, CNTA's ROE is -0.57%, compared to MDGL's ROE of -0.51%. Regarding short-term risk, CNTA is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check MDGL's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, IONS has a market cap of 6.9B. Regarding current trading prices, CNTA is priced at $16.36, while IONS trades at $43.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas IONS's P/E ratio is -24.69. In terms of profitability, CNTA's ROE is -0.57%, compared to IONS's ROE of -0.45%. Regarding short-term risk, CNTA is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check IONS's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, RVMD has a market cap of 6.9B. Regarding current trading prices, CNTA is priced at $16.36, while RVMD trades at $37.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas RVMD's P/E ratio is -9.27. In terms of profitability, CNTA's ROE is -0.57%, compared to RVMD's ROE of -0.37%. Regarding short-term risk, CNTA is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check RVMD's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, CNTA is priced at $16.36, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas RETA's P/E ratio is -66.29. In terms of profitability, CNTA's ROE is -0.57%, compared to RETA's ROE of +0.47%. Regarding short-term risk, CNTA is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check RETA's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, RYTM has a market cap of 5.9B. Regarding current trading prices, CNTA is priced at $16.36, while RYTM trades at $87.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas RYTM's P/E ratio is -32.23. In terms of profitability, CNTA's ROE is -0.57%, compared to RYTM's ROE of -1.80%. Regarding short-term risk, CNTA is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check RYTM's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, NUVL has a market cap of 5.6B. Regarding current trading prices, CNTA is priced at $16.36, while NUVL trades at $78.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas NUVL's P/E ratio is -17.74. In terms of profitability, CNTA's ROE is -0.57%, compared to NUVL's ROE of -0.31%. Regarding short-term risk, CNTA is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check NUVL's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, CNTA is priced at $16.36, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, CNTA's ROE is -0.57%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, CNTA is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check ABCM's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, CNTA is priced at $16.36, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas ISEE's P/E ratio is -22.44. In terms of profitability, CNTA's ROE is -0.57%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, CNTA is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check ISEE's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, ABVX has a market cap of 5.4B. Regarding current trading prices, CNTA is priced at $16.36, while ABVX trades at $68.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas ABVX's P/E ratio is -21.39. In terms of profitability, CNTA's ROE is -0.57%, compared to ABVX's ROE of -1.06%. Regarding short-term risk, CNTA is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check ABVX's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, AXSM has a market cap of 5.2B. Regarding current trading prices, CNTA is priced at $16.36, while AXSM trades at $102.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas AXSM's P/E ratio is -18.46. In terms of profitability, CNTA's ROE is -0.57%, compared to AXSM's ROE of -3.64%. Regarding short-term risk, CNTA is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check AXSM's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, CRSP has a market cap of 5.1B. Regarding current trading prices, CNTA is priced at $16.36, while CRSP trades at $56.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas CRSP's P/E ratio is -13.27. In terms of profitability, CNTA's ROE is -0.57%, compared to CRSP's ROE of -0.20%. Regarding short-term risk, CNTA is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check CRSP's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, MRUS has a market cap of 5B. Regarding current trading prices, CNTA is priced at $16.36, while MRUS trades at $66.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas MRUS's P/E ratio is -16.09. In terms of profitability, CNTA's ROE is -0.57%, compared to MRUS's ROE of -0.41%. Regarding short-term risk, CNTA is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check MRUS's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, ADMA has a market cap of 4.8B. Regarding current trading prices, CNTA is priced at $16.36, while ADMA trades at $19.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas ADMA's P/E ratio is 23.70. In terms of profitability, CNTA's ROE is -0.57%, compared to ADMA's ROE of +0.72%. Regarding short-term risk, CNTA is more volatile compared to ADMA. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check ADMA's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, TGTX has a market cap of 4.6B. Regarding current trading prices, CNTA is priced at $16.36, while TGTX trades at $27.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas TGTX's P/E ratio is 114.88. In terms of profitability, CNTA's ROE is -0.57%, compared to TGTX's ROE of +0.19%. Regarding short-term risk, CNTA is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check TGTX's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, TLX has a market cap of 4.5B. Regarding current trading prices, CNTA is priced at $16.36, while TLX trades at $12.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas TLX's P/E ratio is 148.00. In terms of profitability, CNTA's ROE is -0.57%, compared to TLX's ROE of +0.06%. Regarding short-term risk, CNTA is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check TLX's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, RNA has a market cap of 4.5B. Regarding current trading prices, CNTA is priced at $16.36, while RNA trades at $37.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas RNA's P/E ratio is -12.44. In terms of profitability, CNTA's ROE is -0.57%, compared to RNA's ROE of -0.27%. Regarding short-term risk, CNTA is more volatile compared to RNA. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check RNA's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, CNTA is priced at $16.36, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas ALPN's P/E ratio is -101.52. In terms of profitability, CNTA's ROE is -0.57%, compared to ALPN's ROE of -0.04%. Regarding short-term risk, CNTA is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check ALPN's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, SLNO has a market cap of 4.4B. Regarding current trading prices, CNTA is priced at $16.36, while SLNO trades at $82.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas SLNO's P/E ratio is -17.75. In terms of profitability, CNTA's ROE is -0.57%, compared to SLNO's ROE of -0.78%. Regarding short-term risk, CNTA is more volatile compared to SLNO. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check SLNO's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, ALKS has a market cap of 4.4B. Regarding current trading prices, CNTA is priced at $16.36, while ALKS trades at $26.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas ALKS's P/E ratio is 12.87. In terms of profitability, CNTA's ROE is -0.57%, compared to ALKS's ROE of +0.24%. Regarding short-term risk, CNTA is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check ALKS's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, CYTK has a market cap of 4.4B. Regarding current trading prices, CNTA is priced at $16.36, while CYTK trades at $36.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas CYTK's P/E ratio is -6.91. In terms of profitability, CNTA's ROE is -0.57%, compared to CYTK's ROE of +8.01%. Regarding short-term risk, CNTA is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check CYTK's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, PCVX has a market cap of 4.4B. Regarding current trading prices, CNTA is priced at $16.36, while PCVX trades at $34.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas PCVX's P/E ratio is -8.45. In terms of profitability, CNTA's ROE is -0.57%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, CNTA is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check PCVX's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, ZLAB has a market cap of 4.2B. Regarding current trading prices, CNTA is priced at $16.36, while ZLAB trades at $39.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas ZLAB's P/E ratio is -15.22. In terms of profitability, CNTA's ROE is -0.57%, compared to ZLAB's ROE of -0.33%. Regarding short-term risk, CNTA is more volatile compared to ZLAB. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check ZLAB's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, CNTA is priced at $16.36, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas OPT's P/E ratio is -1.52. In terms of profitability, CNTA's ROE is -0.57%, compared to OPT's ROE of +2.60%. Regarding short-term risk, CNTA is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check OPT's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, PTCT has a market cap of 4.1B. Regarding current trading prices, CNTA is priced at $16.36, while PTCT trades at $51.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas PTCT's P/E ratio is 8.03. In terms of profitability, CNTA's ROE is -0.57%, compared to PTCT's ROE of -0.72%. Regarding short-term risk, CNTA is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check PTCT's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, CNTA is priced at $16.36, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas MRTX's P/E ratio is -4.82. In terms of profitability, CNTA's ROE is -0.57%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, CNTA is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check MRTX's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, ACAD has a market cap of 4B. Regarding current trading prices, CNTA is priced at $16.36, while ACAD trades at $23.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas ACAD's P/E ratio is 17.55. In terms of profitability, CNTA's ROE is -0.57%, compared to ACAD's ROE of +0.35%. Regarding short-term risk, CNTA is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check ACAD's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, ACLX has a market cap of 4B. Regarding current trading prices, CNTA is priced at $16.36, while ACLX trades at $72.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas ACLX's P/E ratio is -24.11. In terms of profitability, CNTA's ROE is -0.57%, compared to ACLX's ROE of -0.35%. Regarding short-term risk, CNTA is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check ACLX's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, KRYS has a market cap of 3.9B. Regarding current trading prices, CNTA is priced at $16.36, while KRYS trades at $134.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas KRYS's P/E ratio is 32.28. In terms of profitability, CNTA's ROE is -0.57%, compared to KRYS's ROE of +0.14%. Regarding short-term risk, CNTA is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check KRYS's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, AKRO has a market cap of 3.9B. Regarding current trading prices, CNTA is priced at $16.36, while AKRO trades at $49.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas AKRO's P/E ratio is -12.97. In terms of profitability, CNTA's ROE is -0.57%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, CNTA is less volatile compared to AKRO. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check AKRO's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, VKTX has a market cap of 3.8B. Regarding current trading prices, CNTA is priced at $16.36, while VKTX trades at $34.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas VKTX's P/E ratio is -22.06. In terms of profitability, CNTA's ROE is -0.57%, compared to VKTX's ROE of -0.20%. Regarding short-term risk, CNTA is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check VKTX's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, CNTA is priced at $16.36, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas RYZB's P/E ratio is -57.86. In terms of profitability, CNTA's ROE is -0.57%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, CNTA is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check RYZB's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, CNTA is priced at $16.36, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas CBAY's P/E ratio is -32.81. In terms of profitability, CNTA's ROE is -0.57%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, CNTA is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check CBAY's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, MTSR has a market cap of 3.6B. Regarding current trading prices, CNTA is priced at $16.36, while MTSR trades at $34.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas MTSR's P/E ratio is -11.71. In terms of profitability, CNTA's ROE is -0.57%, compared to MTSR's ROE of -0.63%. Regarding short-term risk, CNTA is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check MTSR's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, CNTA is priced at $16.36, while SWTX trades at $46.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas SWTX's P/E ratio is -13.78. In terms of profitability, CNTA's ROE is -0.57%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, CNTA is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check SWTX's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, LEGN has a market cap of 3.5B. Regarding current trading prices, CNTA is priced at $16.36, while LEGN trades at $38.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas LEGN's P/E ratio is -32.58. In terms of profitability, CNTA's ROE is -0.57%, compared to LEGN's ROE of -0.20%. Regarding short-term risk, CNTA is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check LEGN's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, SRRK has a market cap of 3.5B. Regarding current trading prices, CNTA is priced at $16.36, while SRRK trades at $36.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas SRRK's P/E ratio is -14.51. In terms of profitability, CNTA's ROE is -0.57%, compared to SRRK's ROE of -1.18%. Regarding short-term risk, CNTA is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check SRRK's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, AAPG has a market cap of 3.5B. Regarding current trading prices, CNTA is priced at $16.36, while AAPG trades at $41.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas AAPG's P/E ratio is -50.13. In terms of profitability, CNTA's ROE is -0.57%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, CNTA is less volatile compared to AAPG. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check AAPG's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, MLTX has a market cap of 3.4B. Regarding current trading prices, CNTA is priced at $16.36, while MLTX trades at $53.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas MLTX's P/E ratio is -23.18. In terms of profitability, CNTA's ROE is -0.57%, compared to MLTX's ROE of -0.31%. Regarding short-term risk, CNTA is more volatile compared to MLTX. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check MLTX's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, PTGX has a market cap of 3.3B. Regarding current trading prices, CNTA is priced at $16.36, while PTGX trades at $53.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas PTGX's P/E ratio is 69.01. In terms of profitability, CNTA's ROE is -0.57%, compared to PTGX's ROE of +0.09%. Regarding short-term risk, CNTA is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check PTGX's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, APLS has a market cap of 3.1B. Regarding current trading prices, CNTA is priced at $16.36, while APLS trades at $24.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas APLS's P/E ratio is -13.26. In terms of profitability, CNTA's ROE is -0.57%, compared to APLS's ROE of -1.16%. Regarding short-term risk, CNTA is less volatile compared to APLS. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check APLS's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, KYMR has a market cap of 3.1B. Regarding current trading prices, CNTA is priced at $16.36, while KYMR trades at $43.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas KYMR's P/E ratio is -14.04. In terms of profitability, CNTA's ROE is -0.57%, compared to KYMR's ROE of -0.30%. Regarding short-term risk, CNTA is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check KYMR's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, CNTA is priced at $16.36, while MORF trades at $56.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas MORF's P/E ratio is -14.88. In terms of profitability, CNTA's ROE is -0.57%, compared to MORF's ROE of -0.22%. Regarding short-term risk, CNTA is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check MORF's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, CNTA is priced at $16.36, while MOR trades at $18.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas MOR's P/E ratio is -12.64. In terms of profitability, CNTA's ROE is -0.57%, compared to MOR's ROE of -1.84%. Regarding short-term risk, CNTA is less volatile compared to MOR. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check MOR's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, IMVT has a market cap of 2.8B. Regarding current trading prices, CNTA is priced at $16.36, while IMVT trades at $16.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas IMVT's P/E ratio is -5.89. In terms of profitability, CNTA's ROE is -0.57%, compared to IMVT's ROE of -0.81%. Regarding short-term risk, CNTA is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check IMVT's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, CNTA is priced at $16.36, while KDNY trades at $40.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas KDNY's P/E ratio is -12.47. In terms of profitability, CNTA's ROE is -0.57%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, CNTA is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check KDNY's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, RARE has a market cap of 2.7B. Regarding current trading prices, CNTA is priced at $16.36, while RARE trades at $28.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas RARE's P/E ratio is -4.88. In terms of profitability, CNTA's ROE is -0.57%, compared to RARE's ROE of -1.86%. Regarding short-term risk, CNTA is less volatile compared to RARE. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check RARE's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, CPRX has a market cap of 2.7B. Regarding current trading prices, CNTA is priced at $16.36, while CPRX trades at $22.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas CPRX's P/E ratio is 13.84. In terms of profitability, CNTA's ROE is -0.57%, compared to CPRX's ROE of +0.28%. Regarding short-term risk, CNTA is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check CPRX's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, CRNX has a market cap of 2.6B. Regarding current trading prices, CNTA is priced at $16.36, while CRNX trades at $28.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas CRNX's P/E ratio is -7.43. In terms of profitability, CNTA's ROE is -0.57%, compared to CRNX's ROE of -0.31%. Regarding short-term risk, CNTA is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check CRNX's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, CNTA is priced at $16.36, while MYOV trades at $26.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas MYOV's P/E ratio is -14.05. In terms of profitability, CNTA's ROE is -0.57%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, CNTA is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check MYOV's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, LGND has a market cap of 2.6B. Regarding current trading prices, CNTA is priced at $16.36, while LGND trades at $134.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas LGND's P/E ratio is -18.57. In terms of profitability, CNTA's ROE is -0.57%, compared to LGND's ROE of -0.16%. Regarding short-term risk, CNTA is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check LGND's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, MIRM has a market cap of 2.6B. Regarding current trading prices, CNTA is priced at $16.36, while MIRM trades at $52.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas MIRM's P/E ratio is -32.43. In terms of profitability, CNTA's ROE is -0.57%, compared to MIRM's ROE of -0.34%. Regarding short-term risk, CNTA is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check MIRM's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, XENE has a market cap of 2.5B. Regarding current trading prices, CNTA is priced at $16.36, while XENE trades at $35.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas XENE's P/E ratio is -10.30. In terms of profitability, CNTA's ROE is -0.57%, compared to XENE's ROE of -0.32%. Regarding short-term risk, CNTA is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check XENE's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, RXRX has a market cap of 2.5B. Regarding current trading prices, CNTA is priced at $16.36, while RXRX trades at $5.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas RXRX's P/E ratio is -3.22. In terms of profitability, CNTA's ROE is -0.57%, compared to RXRX's ROE of -0.75%. Regarding short-term risk, CNTA is less volatile compared to RXRX. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check RXRX's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, KNSA has a market cap of 2.4B. Regarding current trading prices, CNTA is priced at $16.36, while KNSA trades at $33.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas KNSA's P/E ratio is 659.00. In terms of profitability, CNTA's ROE is -0.57%, compared to KNSA's ROE of +0.01%. Regarding short-term risk, CNTA is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check KNSA's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, NAMS has a market cap of 2.4B. Regarding current trading prices, CNTA is priced at $16.36, while NAMS trades at $22.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas NAMS's P/E ratio is -11.77. In terms of profitability, CNTA's ROE is -0.57%, compared to NAMS's ROE of -0.33%. Regarding short-term risk, CNTA is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check NAMS's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, CNTA is priced at $16.36, while PRVB trades at $24.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas PRVB's P/E ratio is -16.43. In terms of profitability, CNTA's ROE is -0.57%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, CNTA is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check PRVB's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, NAMSW has a market cap of 2.3B. Regarding current trading prices, CNTA is priced at $16.36, while NAMSW trades at $10.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas NAMSW's P/E ratio is N/A. In terms of profitability, CNTA's ROE is -0.57%, compared to NAMSW's ROE of -0.33%. Regarding short-term risk, CNTA is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check NAMSW's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, CNTA is priced at $16.36, while LBPH trades at $59.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas LBPH's P/E ratio is -26.66. In terms of profitability, CNTA's ROE is -0.57%, compared to LBPH's ROE of -0.33%. Regarding short-term risk, CNTA is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check LBPH's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, ARWR has a market cap of 2.3B. Regarding current trading prices, CNTA is priced at $16.36, while ARWR trades at $16.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas ARWR's P/E ratio is -13.28. In terms of profitability, CNTA's ROE is -0.57%, compared to ARWR's ROE of -0.46%. Regarding short-term risk, CNTA is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check ARWR's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, BLTE has a market cap of 2.3B. Regarding current trading prices, CNTA is priced at $16.36, while BLTE trades at $65.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas BLTE's P/E ratio is -51.32. In terms of profitability, CNTA's ROE is -0.57%, compared to BLTE's ROE of -0.32%. Regarding short-term risk, CNTA is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check BLTE's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, CNTA is priced at $16.36, while DICE trades at $47.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas DICE's P/E ratio is -21.91. In terms of profitability, CNTA's ROE is -0.57%, compared to DICE's ROE of +0.56%. Regarding short-term risk, CNTA is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check DICE's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, APGE has a market cap of 2.2B. Regarding current trading prices, CNTA is priced at $16.36, while APGE trades at $37.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas APGE's P/E ratio is -10.31. In terms of profitability, CNTA's ROE is -0.57%, compared to APGE's ROE of -0.19%. Regarding short-term risk, CNTA is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check APGE's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, GLPG has a market cap of 2.2B. Regarding current trading prices, CNTA is priced at $16.36, while GLPG trades at $33.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas GLPG's P/E ratio is -6.66. In terms of profitability, CNTA's ROE is -0.57%, compared to GLPG's ROE of -0.10%. Regarding short-term risk, CNTA is more volatile compared to GLPG. This indicates potentially higher risk in terms of short-term price fluctuations for CNTA.Check GLPG's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, IDYA has a market cap of 2.2B. Regarding current trading prices, CNTA is priced at $16.36, while IDYA trades at $25.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas IDYA's P/E ratio is -6.85. In terms of profitability, CNTA's ROE is -0.57%, compared to IDYA's ROE of -0.29%. Regarding short-term risk, CNTA is less volatile compared to IDYA. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check IDYA's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, IBRX has a market cap of 2.2B. Regarding current trading prices, CNTA is priced at $16.36, while IBRX trades at $2.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas IBRX's P/E ratio is -4.21. In terms of profitability, CNTA's ROE is -0.57%, compared to IBRX's ROE of +0.65%. Regarding short-term risk, CNTA is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check IBRX's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, CALT has a market cap of 2.1B. Regarding current trading prices, CNTA is priced at $16.36, while CALT trades at $40.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas CALT's P/E ratio is -22.73. In terms of profitability, CNTA's ROE is -0.57%, compared to CALT's ROE of -1.67%. Regarding short-term risk, CNTA is less volatile compared to CALT. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check CALT's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, FOLD has a market cap of 2.1B. Regarding current trading prices, CNTA is priced at $16.36, while FOLD trades at $6.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas FOLD's P/E ratio is -56.92. In terms of profitability, CNTA's ROE is -0.57%, compared to FOLD's ROE of -0.20%. Regarding short-term risk, CNTA is less volatile compared to FOLD. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check FOLD's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, AGIO has a market cap of 2.1B. Regarding current trading prices, CNTA is priced at $16.36, while AGIO trades at $35.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas AGIO's P/E ratio is 3.13. In terms of profitability, CNTA's ROE is -0.57%, compared to AGIO's ROE of +0.43%. Regarding short-term risk, CNTA is less volatile compared to AGIO. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check AGIO's competition here

CNTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CNTA stands at 2.1B. In comparison, DNLI has a market cap of 2.1B. Regarding current trading prices, CNTA is priced at $16.36, while DNLI trades at $14.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CNTA currently has a P/E ratio of -8.55, whereas DNLI's P/E ratio is -5.41. In terms of profitability, CNTA's ROE is -0.57%, compared to DNLI's ROE of -0.36%. Regarding short-term risk, CNTA is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for CNTA.Check DNLI's competition here